Frequency Therapeutics experimented with using regenerative medicine to reverse hearing loss. They use small molecules to program progenitor cells, a descendant of stem cells in the inner ear, to create the tiny hair cells that allow us to hear. Frequency’s drug is designed to be injected into the ear to regenerate these damaged hair cells within the cochlea. In February 2023, Frequency reported that the results of its Phase 2 clinical trials for this drug were disappointing and that it will cease the development of FX-322. However, the company did not say that it will cease the research, and hopefully, in the near future, they might be able to improve the drug and get better results.